Overall, our findings highlight the need for the molecular re-evaluation of GIST at disease progression and support the exploration of CIK cellular immunotherapy in clinical studies for patients with TKI-resistant, KIT/PDGFRA wild type GIST. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.